Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Fineline Cube Feb 14, 2026
Company Drug

Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review

Fineline Cube Sep 23, 2022

China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276)...

Company Deals

Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform

Fineline Cube Sep 23, 2022

Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to...

Company Deals

Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions

Fineline Cube Sep 23, 2022

Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...

Company Deals

InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade

Fineline Cube Sep 23, 2022

China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...

Company Drug

Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China

Fineline Cube Sep 23, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...

Company Deals

AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion

Fineline Cube Sep 23, 2022

China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...

Company Drug

AstraZeneca and Merck’s Lynparza Receives New Approval in China

Fineline Cube Sep 22, 2022

UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...

Company Deals

Shandong Luoxin Partners with Shanghai Pharma for Strategic Services

Fineline Cube Sep 22, 2022

China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with...

Policy / Regulatory

NHSA Releases Guide on Volume-Based Procurement Drug Equivalents

Fineline Cube Sep 22, 2022

The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...

Company Drug

Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE

Fineline Cube Sep 22, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals Policy / Regulatory

F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review

Fineline Cube Sep 22, 2022

UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...

Company Deals Digital

Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine

Fineline Cube Sep 22, 2022

Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...

Company

Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center

Fineline Cube Sep 22, 2022

German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...

Company Deals

METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program

Fineline Cube Sep 22, 2022

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...

Policy / Regulatory

Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme

Fineline Cube Sep 22, 2022

Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...

Company Deals

Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare

Fineline Cube Sep 21, 2022

Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...

Company Drug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

Fineline Cube Sep 21, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...

Company Deals

Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2

Fineline Cube Sep 21, 2022

Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...

Company Drug

Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Posts pagination

1 … 581 582 583 … 625

Recent updates

  • Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China
  • Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy
  • Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform
  • Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology
  • VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.